Cargando…

CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy

BACKGROUND: Immunotherapy has achieved remarkable advances via a variety of strategies against tumor cells that evade immune surveillance. As important innate immune cells, macrophages play important roles in maintaining homeostasis, preventing pathogen invasion, resisting tumor cells and promoting...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Hongfei, Sun, Yixuan, Zhou, Xiuman, Chen, Chunxia, Jiao, Ling, Li, Wanqiong, Gou, Shanshan, Li, Yanying, Du, Jiangfeng, Chen, Guanyu, Zhai, Wenjie, Wu, Yahong, Qi, Yuanming, Gao, Yanfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537338/ https://www.ncbi.nlm.nih.gov/pubmed/33020240 http://dx.doi.org/10.1136/jitc-2020-000905

Ejemplares similares

Identification of natural product 3, 5-diiodotyrosine as APOBEC3B inhibitor to prevent somatic mutation accumulation and cancer progression
por: Chen, Chunxia, et al.
Publicado: (2022)

Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy
por: Zhou, Xiuman, et al.
Publicado: (2021)

Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy
por: Shen, Wenhui, et al.
Publicado: (2023)

A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8(+) T cell responses
por: Zhai, Wenjie, et al.
Publicado: (2020)

Computer-aided design of PVR mutants with enhanced binding affinity to TIGIT
por: Zhou, Xiaowen, et al.
Publicado: (2021)

BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells
por: van Helden, Mary J, et al.
Publicado: (2023)

Tryptophan 2,3-dioxygenase 2 controls M2 macrophages polarization to promote esophageal squamous cell carcinoma progression via AKT/GSK3β/IL-8 signaling pathway
por: Zhao, Yumiao, et al.
Publicado: (2021)

Adjuvant-free peptide vaccine targeting Clec9a on dendritic cells can induce robust antitumor immune response through Syk/IL-21 axis
por: Gou, Shanshan, et al.
Publicado: (2021)

Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR
por: Zhou, Xiuman, et al.
Publicado: (2020)

Extracellular vesicle IL-32 promotes the M2 macrophage polarization and metastasis of esophageal squamous cell carcinoma via FAK/STAT3 pathway
por: Sun, Yixuan, et al.
Publicado: (2022)

Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer
por: Cao, Xu, et al.
Publicado: (2021)

Identification and optimization of peptide inhibitors to block VISTA/PSGL-1 interaction for cancer immunotherapy
por: Niu, Xiaoshuang, et al.
Publicado: (2023)

HLA-A2-Restricted Epitopes Identified from MTA1 Could Elicit Antigen-Specific Cytotoxic T Lymphocyte Response
por: Wu, Yahong, et al.
Publicado: (2018)

Membrane-Mediated Cooperative Interactions of CD47 and SIRPα
por: Li, Long, et al.
Publicado: (2023)

Restoration of miR-340 controls pancreatic cancer cell CD47 expression to promote macrophage phagocytosis and enhance antitumor immunity
por: Xi, Qing, et al.
Publicado: (2020)

Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity
por: Qu, Tailong, et al.
Publicado: (2022)

Cancer Therapy Targeting CD47/SIRPα
por: Dizman, Nazli, et al.
Publicado: (2021)

Targeting the CD47/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response
por: Stirling, Elizabeth R, et al.
Publicado: (2022)

The SIRPα–CD47 immune checkpoint in NK cells
por: Deuse, Tobias, et al.
Publicado: (2021)

CD47–SIRPα-targeted therapeutics: status and prospects
por: Maute, R., et al.
Publicado: (2022)

Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy
por: Liu, Xia, et al.
Publicado: (2022)

Potential New Cancer Immunotherapy: Anti-CD47-SIRPα Antibodies
por: Lu, Quansheng, et al.
Publicado: (2020)

Insights into CD47/SIRPα axis-targeting tumor immunotherapy
por: Zhang, Xuyao, et al.
Publicado: (2018)

CD47/SIRPα axis: bridging innate and adaptive immunity
por: van Duijn, Anneloes, et al.
Publicado: (2022)

Activation of GM-CSF and TLR2 signaling synergistically enhances antigen-specific antitumor immunity and modulates the tumor microenvironment
por: Yan, Wan-Lun, et al.
Publicado: (2021)

Low molecular weight heparin synergistically enhances the efficacy of adoptive and anti-PD-1-based immunotherapy by increasing lymphocyte infiltration in colorectal cancer
por: Quan, Yibo, et al.
Publicado: (2023)

The design of high affinity human PD-1 mutants by using molecular dynamics simulations (MD)
por: Du, Jiangfeng, et al.
Publicado: (2018)

A novel peptide targeting Clec9a on dendritic cell for cancer immunotherapy
por: Yan, Zhongyi, et al.
Publicado: (2016)

Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis
por: Zhang, Wenting, et al.
Publicado: (2020)

CD47/SIRPα pathway mediates cancer immune escape and immunotherapy
por: Jia, Xiao, et al.
Publicado: (2021)

Identification of HLA-A2-Restricted Mutant Epitopes from Neoantigens of Esophageal Squamous Cell Carcinoma
por: Wang, Zhiwei, et al.
Publicado: (2021)

POTN: A Human Leukocyte Antigen-A2 Immunogenic Peptides Screening Model and Its Applications in Tumor Antigens Prediction
por: Meng, Qingqing, et al.
Publicado: (2020)

IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma
por: Zhang, Wenjie, et al.
Publicado: (2020)

Helicobacter pylori infection disturbs the tumor immune microenvironment and is associated with a discrepant prognosis in gastric de novo diffuse large B-cell lymphoma
por: Deng, Yuwei, et al.
Publicado: (2021)

Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy
por: Chen, Huanpeng, et al.
Publicado: (2022)

Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα–CD47 innate immune checkpoint
por: Voets, Erik, et al.
Publicado: (2019)

Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis
por: Hu, Jinyang, et al.
Publicado: (2020)

Role of CD47-SIRPα Checkpoint in Nanomedicine-Based Anti-Cancer Treatment
por: Liao, Haiqin, et al.
Publicado: (2022)

CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies
por: Bouwstra, Renée, et al.
Publicado: (2022)

Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer
por: Luo, Xukai, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tv987ac558eqc0h4e79j728ftg